The current status of clinical trials on cancer and age disparities among the most common cancer trial participants
Abstract Objective To illustrate the status of all cancer clinical trials and characterize clinical trial enrollment disparities in the most common cancer. Methods Clinical trial data were extracted from ClinicalTrials.gov website. All searched clinical trials were included in the current status ana...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-11690-9 |
| _version_ | 1797363196378480640 |
|---|---|
| author | Shuang Zhao Miao Miao Qingqing Wang Haijuan Zhao Han Yang Xin Wang |
| author_facet | Shuang Zhao Miao Miao Qingqing Wang Haijuan Zhao Han Yang Xin Wang |
| author_sort | Shuang Zhao |
| collection | DOAJ |
| description | Abstract Objective To illustrate the status of all cancer clinical trials and characterize clinical trial enrollment disparities in the most common cancer. Methods Clinical trial data were extracted from ClinicalTrials.gov website. All searched clinical trials were included in the current status analysis of clinical trials on cancer. Among all the clinical trials, only trials addressing single disease sites of breast, prostate, colorectal, or lung (BPCRL) cancer were included in the age disparities analysis. The difference in median age (DMA) between the trial participant median age and the population-based disease-site-specific median age was calculated for each trial. Results A total of 7747 clinical trials were included in the current status analysis of clinical trials on cancer. The number of registered trials had been increasing from 2008 to 2021 (AAPC = 50.60, 95% CI 36.60, 66.00, P < 0.05). Of the 7747 trials, 1.50% (116) of the studies were clinical trials for the elderly aged 60 years or older. 322 trials were included in the age disparities analysis. For all trials, the median DMA was − 8.15 years (P 25, P 75, − 10.83 to − 2.98 years, P < 0.001). The median DMA were − 9.55 years (P 25, P 75, − 11.63 to − 7.11 years), − 7.10 years (P 25, P 75, − 9.80 to − 5.70 years), − 9.75 years (P 25, P 75, − 11.93 to − 7.35 years), 3.50 years (P 25, P 75, 0.60 to 4.55 years), respectively, for breast cancer, colorectal cancer, lung cancer and prostate cancer. Conclusion The numbers of registered clinical trials show an upward trend. Age disparities between trial participants and diagnosed disease population are present in BPCRL cancer trials and appear to be increasing over time. Equitable participation in clinical trials on the basis of age is crucial for advancing medical knowledge and evaluating the safety and efficacy of new treatments that are generalizable to aging populations. |
| first_indexed | 2024-03-08T16:17:45Z |
| format | Article |
| id | doaj.art-d9470e935c454529800a4a962265b7f8 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-08T16:17:45Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-d9470e935c454529800a4a962265b7f82024-01-07T12:30:20ZengBMCBMC Cancer1471-24072024-01-012411810.1186/s12885-023-11690-9The current status of clinical trials on cancer and age disparities among the most common cancer trial participantsShuang Zhao0Miao Miao1Qingqing Wang2Haijuan Zhao3Han Yang4Xin Wang5Clinical Trial Research Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesClinical Trial Research Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesClinical Trial Research Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesClinical Trial Research Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesClinical Trial Research Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesClinical Trial Research Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesAbstract Objective To illustrate the status of all cancer clinical trials and characterize clinical trial enrollment disparities in the most common cancer. Methods Clinical trial data were extracted from ClinicalTrials.gov website. All searched clinical trials were included in the current status analysis of clinical trials on cancer. Among all the clinical trials, only trials addressing single disease sites of breast, prostate, colorectal, or lung (BPCRL) cancer were included in the age disparities analysis. The difference in median age (DMA) between the trial participant median age and the population-based disease-site-specific median age was calculated for each trial. Results A total of 7747 clinical trials were included in the current status analysis of clinical trials on cancer. The number of registered trials had been increasing from 2008 to 2021 (AAPC = 50.60, 95% CI 36.60, 66.00, P < 0.05). Of the 7747 trials, 1.50% (116) of the studies were clinical trials for the elderly aged 60 years or older. 322 trials were included in the age disparities analysis. For all trials, the median DMA was − 8.15 years (P 25, P 75, − 10.83 to − 2.98 years, P < 0.001). The median DMA were − 9.55 years (P 25, P 75, − 11.63 to − 7.11 years), − 7.10 years (P 25, P 75, − 9.80 to − 5.70 years), − 9.75 years (P 25, P 75, − 11.93 to − 7.35 years), 3.50 years (P 25, P 75, 0.60 to 4.55 years), respectively, for breast cancer, colorectal cancer, lung cancer and prostate cancer. Conclusion The numbers of registered clinical trials show an upward trend. Age disparities between trial participants and diagnosed disease population are present in BPCRL cancer trials and appear to be increasing over time. Equitable participation in clinical trials on the basis of age is crucial for advancing medical knowledge and evaluating the safety and efficacy of new treatments that are generalizable to aging populations.https://doi.org/10.1186/s12885-023-11690-9Current statusClinical trialAge disparities |
| spellingShingle | Shuang Zhao Miao Miao Qingqing Wang Haijuan Zhao Han Yang Xin Wang The current status of clinical trials on cancer and age disparities among the most common cancer trial participants BMC Cancer Current status Clinical trial Age disparities |
| title | The current status of clinical trials on cancer and age disparities among the most common cancer trial participants |
| title_full | The current status of clinical trials on cancer and age disparities among the most common cancer trial participants |
| title_fullStr | The current status of clinical trials on cancer and age disparities among the most common cancer trial participants |
| title_full_unstemmed | The current status of clinical trials on cancer and age disparities among the most common cancer trial participants |
| title_short | The current status of clinical trials on cancer and age disparities among the most common cancer trial participants |
| title_sort | current status of clinical trials on cancer and age disparities among the most common cancer trial participants |
| topic | Current status Clinical trial Age disparities |
| url | https://doi.org/10.1186/s12885-023-11690-9 |
| work_keys_str_mv | AT shuangzhao thecurrentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT miaomiao thecurrentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT qingqingwang thecurrentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT haijuanzhao thecurrentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT hanyang thecurrentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT xinwang thecurrentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT shuangzhao currentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT miaomiao currentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT qingqingwang currentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT haijuanzhao currentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT hanyang currentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants AT xinwang currentstatusofclinicaltrialsoncancerandagedisparitiesamongthemostcommoncancertrialparticipants |